NLRP3 inhibitor for use in treating myeloid diseases

TW202639119APending Publication Date: 2026-10-01NOVARTIS AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW114147541
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-12-06
Filing Date
2025-12-04
Publication Date
2026-10-01

Smart Images

  • Figure TWG2TA001078668_001
    Figure TWG2TA001078668_001
  • Figure TWG2TA001078668_002
    Figure TWG2TA001078668_002
  • Figure TWG2TA001078668_003
    Figure TWG2TA001078668_003
Patent Text Reader

Abstract

The present disclosure relates to the field of pharmacy, particularly to a NLRP3 inhibitor, for use in treating myeloid diseases, in particular myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of undetermined significance (CCUS), for the manufacture of a medicament for treating myeloid diseases, in particular myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of undetermined significance (CCUS).
Need to check novelty before this filing date? Find Prior Art